Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies
Optimal antiemetic prophylaxis, with >3 drug classes including steroids, for zolbetuximab-associated nausea/vomiting is important for treatment adherence and maximal clinical benefits.
Authors
- Radhika Ranganath
- Maria Matsangou
- Rupesh Pophale
- Mok Oh (ORCID: https://orcid.org/0000-0002-6338-422X)
- F. Lordick
- C. Matney
- K. Shitara
- E. Smyth
- S.J. Klempner
- G. Gourgioti
Institutions
- Center for Neuro-Oncology (US)
- Astellas Pharma (United Kingdom) (GB)
- National Cancer Center Hospital East (JP)
- Oxford BioMedica (United Kingdom) (GB)
- Center for Cancer Research (US)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105931
- Citations
- 1
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 39.15
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- BeiGene
- Moderna
- National Institute for Health and Care Research
- Eisai
- Astellas Pharma
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Daiichi Sankyo Europe